Drug Profile
Zaleplon inhalation - Alexza Pharmaceuticals
Alternative Names: AZ-007; Staccato zaleplonLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Alexza Pharmaceuticals
- Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Insomnia
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Insomnia(In volunteers) in USA (Inhalation, Aerosol)
- 09 Mar 2015 Phase-I clinical trials in Insomnia (In volunteers) in USA (Inhalation)
- 09 Mar 2015 Alexza Pharmaceuticals plans a phase II trial for Insomnia (9175748; 254594)